TTI-200.7

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTTI-200.7
Drug Alias NameCD200 checkpoint inhibitor (Trillium Therapeutics)CD200-specific monoclonal antibody (TTI)anti-OX2 mAb (Trillium Therapeutics)TTI-200
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionOX-2 membrane glycoprotein inhibitors
TargetsOX-2 membrane glycoprotein
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesTrillium Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTrillium Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A